(Lymph)angiogenic influences on hematopoietic cells in acute myeloid leukemia.
- Author:
Ji Yoon LEE
1
;
Hee Je KIM
Author Information
- Publication Type:Research Support, Non-U.S. Gov't ; Review
- MeSH: Animals; Cytokines/*immunology; Hematopoietic Stem Cells/immunology/*pathology; Humans; Immunity, Cellular; Leukemia, Myeloid, Acute/immunology/*physiopathology; *Lymphangiogenesis; Lymphatic Vessels/immunology/*physiopathology; Vascular Endothelial Growth Factor A/immunology
- From:Experimental & Molecular Medicine 2014;46(11):e122-
- CountryRepublic of Korea
- Language:English
- Abstract: The purpose of this review is to provide an overview of the effect of (lymph)angiogenic cytokines on hematopoietic cells involved in acute myeloid leukemia (AML). Like angiogenesis, lymphangiogenesis occurs in pathophysiological conditions but not in healthy adults. AML is closely associated with the vasculature system, and the interplay between lymphangiogenic cytokines maintains leukemic blast survival in the bone marrow (BM). Once AML is induced, proangiogenic cytokines function as angiogenic or lymphangiogenic factors and affect hematopoietic cells, including BM-derived immune cells. Simultaneously, the representative cytokines, VEGFs and their receptors are expressed on AML blasts in vascular and osteoblast niches in both the BM and the peripheral circulation. After exposure to (lymph)angiogenic cytokines in leukemogenesis and infiltration, immune cell phenotypes and functions are affected. These dynamic behaviors in the BM reflect the clinical features of AML. In this review, we note the importance of lymphangiogenic factors and their receptors in hematopoietic cells in AML. Understanding the functional characterization of (lymph)angiogenic factors in the BM niche in AML will also be helpful in interrupting the engraftment of leukemic stem cells and for enhancing immune cell function by modulating the tumor microenvironment.
